Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome - Wikidata - awgldk - TriplyDB

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

http://www.wikidata.org/entity/Q34570954

about

GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.Hypothalamic obesity in children.Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.Obesity management in Prader-Willi syndrome: current perspectives

P2860

Q37213617-3069659C-A138-414D-BE18-91CE96C6578E Q37439977-4CCB31E4-4518-4751-AE8F-213EB198EF1E Q38009341-BB2C0C25-893C-48C5-8AF3-F50E6096AB81 Q38638685-091DFA37-6339-4360-84FC-EF93D32A4E52 Q42343442-1C097F40-8000-46C4-A25C-EC0F17B6CC01 Q45205513-827C8BF4-20B4-4E0D-91CD-D3B28C9F7BDB Q48269619-D5B6BA97-549F-4B30-8701-CD6539A288E6 Q57483607-6B2829E1-A95C-4BB7-BCEA-B681894C46BB

P2860

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

http://www.wikidata.org/entity/Q34570954

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@ast

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@en

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@nl

type

label

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@ast

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@en

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@nl

prefLabel

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@ast

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@en

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@nl

P1433

Q34570954-76CDCEF1-43A1-4EA2-B953-639D5A69F98D

P1476

Q34570954-7B46F574-F766-414B-A029-164AC203EE35

P2093

Q34570954-0604C644-CAE9-459E-BDA4-387FC2644AAD

Q34570954-15B49A40-0001-46EA-9746-75E57F5D2ECB

Q34570954-597B5246-F505-403E-8FAF-74E059734CB5

Q34570954-663456E6-6A21-4FD4-AEC3-3BE0A5F13DC6

Q34570954-B88785C4-1807-4FDF-A3E8-DA21E4D3DF2D

Q34570954-CA1F5246-12DB-40BA-843F-51435D0023D2

P2860

Q34570954-086D9454-8A94-427A-92E5-6F6AACE9D1ED

Q34570954-09E7A445-9840-4D5A-B729-D6829667578F

Q34570954-0BEF6953-A67F-499F-BCD9-D4A5DC479251

Q34570954-1D1C4ECA-94DB-4692-8DD3-15FCECFD3EE3

Q34570954-20B46EC5-A122-43A4-BE58-BF9F749DCC93

Q34570954-21F2C9C6-AB1F-496A-A525-E4979816F177

Q34570954-304D907B-DDD1-40A4-8C7C-D715C26C199F

Q34570954-341EEE71-C6D9-4669-B935-80D8E64F9F8A

Q34570954-3C1AFD9B-78AF-49CB-A1D6-9EA29C7FA083

Q34570954-46C4CBEA-DD0E-44C8-B3F0-0DD501F1AD80

P304

Q34570954-48B6EACA-A7B9-403E-B4D6-4B4F520B69C1

P31

Q34570954-9F90C626-BC07-49FD-AAD5-C79A9DD0BA83

P356

Q34570954-2C56FC35-FDF4-46B9-A708-9B586193D8EC

P433

Q34570954-40970487-B628-4FCA-A1FE-B227A3C3EE38

P478

Q34570954-B184881D-3497-484A-9DC5-23BF545F1BB8

P577

Q34570954-D17ACB67-C22F-4762-9588-67E0E7991AE3

P5875

Q34570954-540DF9EB-5404-4C63-AFC3-5DE2DF514535

P698

Q34570954-1B7F6185-E719-4335-AC94-CB3B0BE4097E

P932

Q34570954-BDE3B09A-DE70-434A-A197-4FB0050A95F8

P356

J.EJMG.2010.09.015

P1433

European Journal of Medical Genetics

P1476

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

@en

P2093

Elizabeth G Lipman

http://www.w3.org/2001/XMLSchema#string

Jeannette E Hogg

http://www.w3.org/2001/XMLSchema#string

Maria G Vogiatzi

http://www.w3.org/2001/XMLSchema#string

Moris A Angulo

http://www.w3.org/2001/XMLSchema#string

Paul J Christos

http://www.w3.org/2001/XMLSchema#string

Roja Motaghedi

http://www.w3.org/2001/XMLSchema#string

P2860

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

Narrative review: the role of leptin in human physiology: emerging clinical applications

The hospital anxiety and depression scale

Leptin-regulated endocannabinoids are involved in maintaining food intake

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

A role for ghrelin in the central regulation of feeding

Prader-Willi syndrome: consensus diagnostic criteria.

High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome.

The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.

P304

14-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJMG.2010.09.015

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47519094

http://www.w3.org/2001/XMLSchema#string

P698

20965292

http://www.w3.org/2001/XMLSchema#string

P932

3038245

http://www.w3.org/2001/XMLSchema#string